Información del artículo
Hoy día se considera que la osteoporosis es un problema de salud pública que justifica la implementación de medidas preventivas y terapéuticas eficaces. El objetivo primario debe ser prevenir la primera fractura y preservar la integridad ósea, aumentando la masa ósea y mejorando la calidad del hueso. Los suplementos de calcio y vitamina D deben recomendarse en todos los individuos de riesgo, y cuando estén indicados deben administrarse fármacos antiosteoporóticos. La evidencia aporta resultados satisfactorios con los fármacos antirresortivos usados actualmente; además, futuros agentes anabólicos permitirán establecer pautas combinadas de tratamiento.
Osteoporosis is a worldwide public health issue and effective preventive and therapeutic strategies should be implemented.
The primary aim should be to prevent the first fracture by increasing bone mass and improving bone quality.
Calcium and vitamin D supplementation should be recommended to all at-risk patients in addition to antiosteoporotic drugs, when indicated. There is strong evidence of the antifracture efficacy of the antiresorptive drugs that are currently used and in future we will be able to use combined therapies with anabolic agents.
Palabras clave:
Osteoporosis
Tratamiento
Prevención
Calcio
Vitamina D
Bifosfonatos
SERM
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. De Laet, J. Revee.
Epidemiology of osteoporotic fractures in Europe.
Osteoporosis, 1 (2001), pp. 585-597
[2.]
B. Dawson-Hughes, S.S. Harris, S. Finneran.
Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype.
J Clin Endocrinol Metab, 80 (1995), pp. 3657-3661
[3.]
R.P. Heany.
Calcium, dairy productos and osteoporosis.
J Am Coll Nutr, 19 (2000), pp. S83-S99
[4.]
National Academy of Sciences.
Recommended dietary allowances.
[5.]
P. Burckhardt.
Calcium and vitamin D in osteoporosis: supplementation of treatment?.
Calcified Tissue Int, 70 (2002), pp. 74-77
[6.]
A. Fontana, P.D. Delmas.
Selective estrogen receptor modulators in the prevention and treatment of postmenopausal osteoporosis.
Endocrinol Metab Clin North Am, 32 (2003), pp. 219-232
[7.]
S.R. Cummings, S. Eckert, K.A. Kruegoer, D. Grady, T.J. Powlee, J.A. Couley, et al.
The effect of raloxifene on the risk of breast cancer in postmenopausal women.
JAMA, 281 (1999), pp. 2189-2197
[8.]
P.D. Delmas, K.E. Ensrud, J.D. Adachi, K.D. Harper, S. Sarkars, Geannari, et al.
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four year results from a randomized clinical trial.
J Clin Endocrinol Metab, 87 (2002), pp. 3609-3617
[9.]
S. Sarkar, B. Mitlak, M. Wong, J.L. Stock, D.M. Blak, K.D. Harper.
Relationship between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
J Bone Miner Res, 17 (2002), pp. 1-10
[10.]
K.M. Prestwood, M. Gunness, D.B. Muchmore, Y. Lu, M. Wong, L.G. Raisz.
A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
J Clin Endocrinol Metab, 85 (2000), pp. 2197-2202
[11.]
The MORE Study Group.
The effect of raloxifene on risk of breast cancer in postmenopausal women.
JAMA, 281 (1999), pp. 2189-2197
[12.]
The MORE Study Group.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene.
JAMA, 288 (1999), pp. 637-645
[13.]
H.A. Pols, D. Felsenberg, D.A. Handley, J. Stepon, M. Muñoz Torres, T.J. Wilkin, et al.
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study.
Osteoporos Intern, 9 (1999), pp. 461-468
[14.]
H. Fleisch.
Biophosphonates: mechanism of action.
Endocr Rev, 19 (1998), pp. 80-100
[15.]
W.M. Hart, C. Tubio Terres, A. Burrel, I. Aristegui, F. Escobar-Jiménez.
Análisis farmacoeconómico del tratamiento de la osteoporosis posmenopáusica con risendronato o alendronato.
REEMO, 11 (2002), pp. 97-104
[16.]
B.E. Nordin.
Should the treatment of osteoporosis be more selective?.
Osteoporos Int, 14 (2003), pp. 99-102
[17.]
M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, C. Roux, et al.
Effect of risedronate on the risk of hip fracture in elderly women.
N Engl J Med, 344 (2001), pp. 333-340
[18.]
J.P. Brown, D.L. Kendler, M.R. McCling, R.D. Emkey, J.D. Adachi, M.A. Bolognese, et al.
The efficacy and tolerability of risedronate once a wee for the treatment of postmenopausal osteoporosis.
Calcif Tissue Int, 71 (2002), pp. 103-111
[19.]
F.L. Lanza, R.H. Hunt, A.B.R. Thomson, J.M. Provenza, M.A. Blank.
for the Risedronate Endoscopy Study Group. Endoscopic comparison of esophageal and gastroduodenal effects of risedronte and alendronate in postmenopausal women.
Gastroenterology, 119 (2000), pp. 631-638
[20.]
J. Reginster, H.W. Minne, O.H. Sorensen, M. Hooper, C. Roux, M. Brandi, et al.
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.
Osteoporos Int, 11 (2000), pp. 83-91
[21.]
S.T. Harris, N.B. Watts, H.K. Genant, D. Mckeever, T. Hangartner, M. Keller, et al.
Effects of risedronate treatment on vertebral ad nonvertebral fractures in women with postmenopausal osteoporosis.
JAMA, 282 (1999), pp. 1344-1352
[22.]
I. Fogelman, C. Ribot, R. Smith, D. Etlige, E. Sod, J.Y. Reginster.
Risedronate reverses bone loss in postmenopausal women with low bone mass: results form a multinational, double-blind, placebo-controlled trial.
J Clin Endocrinol Metab, 85 (2000), pp. 1895-1900
[23.]
A. Cranney, P. Tugwell, J. Adachi, B. Weaver, N. Zytaruk, A. Papaioannou, et al.
Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Endocr Rev, 23 (2002), pp. 517-523
[24.]
A. Cranney, G. Wells, A. Willan, L. Griffith, N. Zytaruk, V. Robinson, et al.
Meta-analysis of alendronate for the treatment of postmenopausal women.
Endocr Rev, 23 (2002), pp. 508-516
[25.]
The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.
Meta-analysis of therapies for postmenopausal osteoporosis.
Endocr Rev, 23 (2002), pp. 496-507
[26.]
A. Cranney, G. Guyatt, L. Griffith, G. Wells, P. Tugwell, C. Rosen.
The Osteoporosis Methodology Group and the Osteoporosis. Summary of meta-analyses of therapies for postmenopausal osteoporosis.
Endocr Rev, 23 (2002), pp. 570-578
[27.]
O. Johnell, W.H. Scheele, Y. Lu, J.Y. Reginster, A.G. Need, E. Seeman.
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab, 87 (2002), pp. 985-992
[28.]
S.J. Wimalawansa.
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Am J Med, 104 (1998), pp. 219-226
[29.]
E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Grahams, et al.
Alendronate for the treatment of osteoporosis in men.
N Engl J Med, 343 (2000), pp. 604-610
[30.]
M.R. Rubin, J.P. Bilezikian.
New anabolic therapies in osteoporosis.
Endocrinol Metab Clin N Am, 32 (2003), pp. 285-307
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición
